Health & Biotech
Check out the latest Cannabis news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts.
Health & Biotech
Weed Week: Massive study links cannabis to genetics and schizophrenia, and the best ASX weed stocks right now
News
ASX Small Caps Market Wrap: Which one of the seven signs of the weed apocalypse dropped this morning?
Health & Biotech
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
News
In Case You Missed It: Record monthly Canadian cannabis revenue takes top spot
News
10 at 11ish: First Au gets nod for bulk sampling at Victorian gold project
Health & Biotech
‘Current inventory moving very quickly’: Melodiol’s Canadian subsidiary continues to deliver record revenue
News
Quarterly Wrap: Pot stocks shine with record revenues for Melodiol, 75pc increase in revenue for Bioxyne
Health & Biotech
Weed Week: US House Speaker ousting could boost weed stocks; TGA urged to allow the term ‘medicinal cannabis’
Health & Biotech
Bioxyne subsidiary imports $3.2million of premium quality cannabis flower into Australia
Health & Biotech
Melodiol marks another record revenue quarter with $7.5m of unaudited sales, up 265% on the PCP
Health & Biotech
Melodiol jumps 20pc as subsidiary Health House International’s Aussie operations deliver quarterly profit
Health & Biotech
Weed Week: Big win for cannabis as SAFER Banking Act approved; market remains robust in Australia
Health & Biotech
‘Nothing short of exceptional’: Melodiol’s psychedelics subsidiary shows promising Phase II PTSD trial results
Health & Biotech
Record sales drive third straight quarter of revenue growth for Melodiol subsidiary Mernova
News
ECS Exclusive: How we pulled off the biggest cross-border pot deal in Aussie history
News
Top 10 at 11: Solid drilling results and a massive dope deal have tongues wagging today
Health & Biotech
Sales highs continue for Melodiol as it grows its Mernova footprint right across Canada
Health & Biotech
Weed Week: Short sellers burned as cannabis stocks stage a rebound. Where to next?
Health & Biotech
Canadian cannabis drive: Melodiol subsidiary Mernova scores first purchase order from Alberta
Health & Biotech
Weed Week: Growing excitement for cannabis stocks after marijuana rescheduling hopes in the US
Health & Biotech
‘Extremely positive news’: Melodiol welcomes US move to shift marijuana to less risky federal drug classification
Health & Biotech
Weed Week: ‘Welcome to the psychedelic 2020s!’ as market holds breath on key US approval
Health & Biotech
‘Frontrunner within the psychedelics’ : Incannex prepares to file psilocybin US FDA application ahead of Nasdaq Uplisting
Health & Biotech
Incannex gets green light from US FDA for Phase 2/3 Pivotal Clinical Trialfor obstructive sleep apnoea
Health & Biotech
‘Significant growth’: Melodiol’s Canadian subsidiary Mernova builds Q3 sales momentum
Health & Biotech
Bioxyne embraces AI revolution with B2B marketplace JV targeting expansion of Australia’s cannabis industry
Health & Biotech
Weed Week: Mastercard says NO to cannabis transactions, as New York becomes the happening place for weed
Health & Biotech
Incannex’s subsidiary Clarion Clinics prepares to take first clients for psychedelic treatment
Health & Biotech
Melodiol looks to streamline portfolio with up to A$30m asset sale to US-listed Panacea
Health & Biotech
MGC Pharma nabs import approval for psilocybin to Slovenian research facility
Health & Biotech
Incannex has positive Pre-IND meeting with US FDA on IHL-675A for treatment of Rheumatoid Arthritis
Health & Biotech
Melodiol closing in on EU GMP licence to fast track cannabis exports to attractive Australian and European markets
Health & Biotech
Melodiol’s encouraged by new subsidiary Health House International’s strong first half CY2023 results
Health & Biotech
Bioxyne’s Dr Watson brand extends its Amazon footprint into US and Japan
Health & Biotech
Melodiol starts Q3 strong with $1.6m in revenue and confirmed purchase orders
IPO Watch
IPO Watch: UK-leading cannabis health and wellness house Dragonfly Biosciences set to list on ASX
Health & Biotech
Why Neurotech is happy following in the footsteps of 2023 biotech market darling Neuren
Health & Biotech
Incannex engages Fortrea for major clinical trial looking at IHL-42X for sleep apnoea
Health & Biotech
Stock Insiders: Bioxyne acquires Breathe Life Sciences with consumer favourite brand Dr Watson
Health & Biotech
Incannex receives ethics approval to start Phase 2 clinical trial for combination drug for rheumatoid arthritis
Health & Biotech
Weed Week: Social media platforms scramble to update advertising policies on cannabis products
News
In Case You Missed It: Cannabis takes the lead, plus some iron ore and nickel
News
Closing Bell: ASX finishes in the green, Real Estate leads the charge
Health & Biotech
Melodial Global Health delivers record revenue quarter with 105pc uptick in group sales
Health & Biotech
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
Health & Biotech
Incannex plans to redomicile to US with sole NASDAQ listing – we look at the arithmetic
Health & Biotech
Melodiol’s Canadian subsidiary Mernova reports 42pc lift in Q2 FY23 revenues and record half yearly results
Load More
